---
title: "Kailera Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295709127.md"
datetime: "2026-08-12T20:58:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295709127.md)
  - [en](https://longbridge.com/en/news/295709127.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295709127.md)
generator: "portal-rs"
---

# Kailera Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -111.31 M.

The provided reference explicitly states that actual financial and operational metrics, as well as any outlook or guidance for Kailera Therapeutics, Inc. for the quarter ended June 30, 2026, are not included within the text provided.

### Related Stocks

- [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md)

## Related News & Research

- [2 GLP-1 Stocks That Could Double Your Money by 2031](https://longbridge.com/en/news/296030914.md)
- [Kailera falls after late-stage trial data for oral GLP-1 candidate](https://longbridge.com/en/news/291956789.md)
- [Kailera reports Phase 3 China data showing up to 10.9% weight loss with oral GLP-1 drug KAI-7535](https://longbridge.com/en/news/291921193.md)
- [Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | KLRA Stock News](https://longbridge.com/en/news/287673757.md)
- [Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287949963.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**